Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;16(1):90-7.
doi: 10.5588/ijtld.11.0153.

Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting

N R Gandhi  1 , J R Andrews, J C M Brust, R Montreuil, D Weissman, M Heo, A P Moll, G H Friedland, N S Shah
Affiliations

Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting

N R Gandhi et al. Int J Tuberc Lung Dis. 2012 Jan.

Abstract

Setting: Recent studies suggest that the prevalence of drug-resistant tuberculosis (TB) in sub-Saharan Africa may be rising. This is of concern, as human immunodeficiency virus (HIV) co-infection in multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB has been associated with exceedingly high mortality rates.

Objective: To identify risk factors associated with mortality in MDR- and XDR-TB patients co-infected with HIV in South Africa.

Design: Case-control study of patients who died of all causes within 2 years of diagnosis with MDR- or XDR-TB.

Results: Among 123 MDR-TB patients, 78 (63%) died following diagnosis. CD4 count ≤ 50 (HR 4.64, P = 0.01) and 51-200 cells/mm(3) (HR 4.17, P = 0.008) were the strongest independent risk factors for mortality. Among 139 XDR-TB patients, 111 (80%) died. CD4 count ≤ 50 cells/mm(3) (HR 4.46, P = 0.01) and resistance to all six drugs tested (HR 2.54, P = 0.04) were the principal risk factors. Use of antiretroviral therapy (ART) was protective (HR 0.34, P = 0.009).

Conclusions: Mortality due to MDR- and XDR-TB was associated with greater degree of immunosuppression and drug resistance. Efforts to reduce mortality must focus on preventing the amplification of resistance by strengthening TB treatment programs, as well as reducing the pool of immunosuppressed HIV-infected patients through aggressive HIV testing and ART initiation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival among patients with multidrug-resistant tuberculosis from the time of sputum collection.
Figure 2
Figure 2
Survival among patients with extensively drug-resistant tuberculosis from the time of sputum collection.
See this image and copyright information in PMC

References

    1. World Health Organization Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva. 2010
    1. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 375:1830–43. - PubMed
    1. Chirenda J, Menzies H, Moalosi G, et al. The trend of resistance to anti-tuberculosis drugs in Botswana: results from the 4th national anti-tuberculosis drug resistance survey.. Programs and Abstracts from the 40th Union World Conference on Lung Health; Cancun, Mexico. Dec 3-7, 2009.2009.
    1. Buthelezi SSS. Situational Analysis of TB Drug Resistance in KwaZulu-Natal Province: Republic of South Africa.. 2nd Meeting of the Global XDR TB Task Force; Geneva, Switzerland. April 9, 2008.
    1. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis. 2008;14:1345–52. - PMC - PubMed

Publication types

MeSH terms

Substances